What this is
- How it works
- Sphingosine 1-phosphate Receptor Modulator FDA class
- How it’s given
- “Administrated orally once daily: 0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less.”In the company’s words, NCT01892722 on ClinicalTrials.gov
- Tested for
- Multiple Sclerosis (2 trials), Multiple Sclerosis (MS)
- Main trialPhase 4
- “The purpose of the study is to describe the safety profile of fingolimod in the Taiwanese multiple sclerosis population. This study aims to collect the safety data in patients newly initiated on fingolimod for one year.”In the company’s words, NCT04480853 on ClinicalTrials.gov
- Other names
- FTY720
Other drugs for Multiple Sclerosis
- IMU-838Immunic AG · Phase 3
- CT-P53Celltrion · Phase 3
- ABP 692Amgen · Phase 3
- FrexalimabSanofi · Phase 3
- Peginterferon beta-1aBiogen · Phase 3
- PrivosegtorOculis · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 15 Oct 2026 | Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis | |
| Phase 3Active, not recruiting | 14 Jul 2017 | Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis | |
| Phase 3Active, not recruiting | 25 Mar 2026 | Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis | |
| Phase 4Completed | 13 Jul 2015 | Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. | |
| Phase 4Completed | 5 Mar 2019 | A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod | |
| Phase 4Completed | 24 Jan 2020 | Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks | |
| Phase 4Completed | 25 Mar 2025 | Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients | |
| Phase 3Completed | 19 Oct 2018 | Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026